Study summary

Two pre-surgery approaches gave the same survival

PREOPANC-2 trial · 369 people, phase 3, randomized · Published September 2025, Lancet Oncology

21.9 momedian survival with pre-surgery FOLFIRINOX, vs 21.3

What was tested

FOLFIRINOX chemotherapy against gemcitabine-based chemoradiation before surgery for pancreatic cancer that can or nearly can be removed.

What they found

Median survival was 21.9 vs 21.3 months, no meaningful difference.
Diarrhea was more common with FOLFIRINOX.

What it means

Either approach is reasonable before surgery; the choice can depend on side effects.

Lancet Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.